RxDoctor Payments Data

Edward O'Leary, MD

Family Medicine · Scottsdale, AZNPI 1841210747

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 11 payments — averaging $98.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$647
  • AbbVie$147
  • GSK$125
  • Astellas Pharma US Inc$100
  • Abiomed$62

What the payments were for

  • Food & beverage$94187%
  • Education$14013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$647
AbbVie(2 entities)2$147
GSK1$125
Astellas Pharma US Inc1$100
Abiomed1$62

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 70th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$189,881
Medicare patients
396
Services billed
2,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$66,599
OzempicSemaglutide41$46,085
MounjaroTirzepatide31$30,389
JardianceEmpagliflozin23$30,209
TrulicityDulaglutide14$26,051
Spiriva RespimatTiotropium Bromide13$20,547
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$17,046
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$6,077
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$5,694
Rosuvastatin Calcium359$4,323
Gabapentin146$4,051
Levothyroxine Sodium358$3,583
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$3,539
Atorvastatin Calcium381$3,295
Valsartan206$3,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$147$2,27925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →